Lymphoma
Conditions
Brief summary
The goal of this retrospective study is to compare between the case cohort and control cohort. The case cohort consists of lymphoma patients treated with novel immunotherapy regimen including Chimeric antigen receptor T cell therapy, bispecfic antibody, and/or antibody-drug conjugate. The control cohort consists of lymphoma patients who received conventional chemotherapy as standard-of-care The main question\[s\] it aims to answer are: * Survival times * Response outcomes
Detailed description
1. Primary endpoints Comparison of survival time by treatment between two groups 2. Secondary endpoints 2.1 Comparison of progression-free survival between two groups 2.2 Comparison of response rates between two groups 2.3 Comparison of input medical costs between two groups. 2\. Study subjects: Patients treated for lymphoma at Yeouido St. Mary's Hospital and Seoul St. Mary's Hospital (Both are located on Seoul, Korea) between May 2009 and June 2023. 3\. Selection criteria: 3.1 Patients diagnosed with malignant lymphoma at Catholic Yeouido St. Mary's Hospital and Seoul St. Mary's Hospital between May 2009 and June 2023. 3.2 Age 19 or older. 3.3 Patients who treated with salvage chemotherapy for the relapsed/refractory lymphoma. 4\. Exclusion criteria: 4.1 Patients suffering from acute leukemia. 4.2 Patients additionally diagnosed with solid cancer (colon cancer, lung cancer, stomach cancer, etc.) during treatment.
Interventions
DRUGImmunotherapy
Immunotherapy
Sponsors
Seoul St. Mary's Hospital
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Inclusion criteria
1. Patients diagnosed with malignant lymphoma at Catholic Yeouido St. Mary's Hospital and Seoul St. Mary's Hospital between May 2009 and June 2023. 2. Age 19 or older. 3. Anti-cancer salvage chemotherpay for the treatment of relapsed/refractory lymphoma.
Exclusion criteria
1. Patients suffering from acute leukemia. 2. Patients additionally diagnosed with solid cancer (colon cancer, lung cancer, stomach cancer, etc.) during treatment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Comparison of Survival Periods Among Groups Comparison of Survival Periods Among Groups | Time Frame: Up to 2 years | overall survival |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Comparison of Progression-Free Survival Periods | Time Frame: Up to 2 years | progression-free survival |
Other
| Measure | Time frame | Description |
|---|---|---|
| Comparison of Response Rates | Time Frame: Up to 2 years | response rate |
| Comparison of Healthcare Costs | Time Frame: Up to 2 years | costs |
Countries
South Korea
Outcome results
None listed